Savara Inc Share Price Nyse
Equities
US5763141083
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
01:39pm | Savara's Phase 3 Trial for Molgramostim Nebulizer Solution Meets Primary Endpoint; Shares Rise Pre-Bell | MT |
12:39pm | Savara's rare lung disease drug meets main goal in late-stage study | RE |
Sales 2024 * | - | Sales 2025 * | 4.9M 387M | Capitalization | 525M 41.48B |
---|---|---|---|---|---|
Net income 2024 * | -79M -6.24B | Net income 2025 * | -69M -5.45B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 107 x |
P/E ratio 2024 * |
-9.17
x | P/E ratio 2025 * |
-8.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.37% |
Latest transcript on Savara Inc
Managers | Title | Age | Since |
---|---|---|---|
Matthew Pauls
CEO | Chief Executive Officer | 53 | 26/04/17 |
David Lowrance
DFI | Director of Finance/CFO | 56 | 26/04/17 |
Robert Lutz
COO | Chief Operating Officer | 55 | 12/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Ramsay
BRD | Director/Board Member | 59 | 26/04/17 |
Richard Hawkins
BRD | Director/Board Member | 75 | 30/09/10 |
Nevan Elam
BRD | Director/Board Member | 56 | 31/01/09 |
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+21.96% | 116B | |
+24.13% | 27.03B | |
-20.05% | 20.36B | |
-16.40% | 16.43B | |
-16.28% | 15.91B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |